272 related articles for article (PubMed ID: 21519360)
21. The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial.
Orr WC; Goodrich S; Wright S; Shepherd K; Mellow M
Neurogastroenterol Motil; 2012 Jun; 24(6):553-9, e253. PubMed ID: 22404184
[TBL] [Abstract][Full Text] [Related]
22. Obesity does not affect treatment outcomes with proton pump inhibitors.
Sharma P; Vakil N; Monyak JT; Silberg DG
J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
[TBL] [Abstract][Full Text] [Related]
23. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
Watson TJ; Peters JH
Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
[TBL] [Abstract][Full Text] [Related]
24. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
[TBL] [Abstract][Full Text] [Related]
25. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
Gold BD; Gunasekaran T; Tolia V; Wetzler G; Conter H; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):520-9. PubMed ID: 18030228
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
28. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
Björnsson E; Abrahamsson H; Simrén M; Mattsson N; Jensen C; Agerforz P; Kilander A
Aliment Pharmacol Ther; 2006 Sep; 24(6):945-54. PubMed ID: 16948806
[TBL] [Abstract][Full Text] [Related]
29. Combination of PPI with a prokinetic drug in gastroesophageal reflux disease.
Ndraha S
Acta Med Indones; 2011 Oct; 43(4):233-6. PubMed ID: 22156354
[TBL] [Abstract][Full Text] [Related]
30. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
[TBL] [Abstract][Full Text] [Related]
31. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.
Kahrilas PJ; Fennerty MB; Joelsson B
Am J Gastroenterol; 1999 Jan; 94(1):92-7. PubMed ID: 9934737
[TBL] [Abstract][Full Text] [Related]
32. Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial.
Flook NW; Moayyedi P; Dent J; Talley NJ; Persson T; Karlson BW; Ruth M
Am J Gastroenterol; 2013 Jan; 108(1):56-64. PubMed ID: 23147520
[TBL] [Abstract][Full Text] [Related]
33. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
[TBL] [Abstract][Full Text] [Related]
34. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect?
Kushner PR; Peura DA
Adv Ther; 2011 May; 28(5):367-88. PubMed ID: 21484335
[TBL] [Abstract][Full Text] [Related]
35. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease.
Mearin F; Ponce J; Ponce M; Balboa A; Gónzalez MA; Zapardiel J
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):665-74. PubMed ID: 22330237
[TBL] [Abstract][Full Text] [Related]
36. Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.
Choung RS; Locke GR; Francis DD; Katzka D; Winkle PJ; Orr WC; Crowell MD; Devault K; Harmsen WS; Zinsmeister AR; Talley NJ
Neurogastroenterol Motil; 2014 Jan; 26(1):13-20. PubMed ID: 24001105
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
38. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients.
Kim JH; Sinn DH; Son HJ; Kim JJ; Rhee JC; Rhee PL
J Gastroenterol Hepatol; 2009 Sep; 24(9):1504-9. PubMed ID: 19467139
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
[TBL] [Abstract][Full Text] [Related]
40. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Farley A; Wruble LD; Humphries TJ
Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
